Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00808132




Registration number
NCT00808132
Ethics application status
Date submitted
12/12/2008
Date registered
15/12/2008
Date last updated
8/04/2014

Titles & IDs
Public title
Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
Scientific title
A Double-Blind, Randomized, Placebo And Active- Controlled Efficacy And Safety Study Of The Effects Of Bazedoxifene/Conjugated Estrogens Combinations On Endometrial Hyperplasia And Prevention Of Osteoporosis In Postmenopausal Women
Secondary ID [1] 0 0
B2311009
Secondary ID [2] 0 0
3115A1-3307
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Menopause 0 0
Osteoporosis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoporosis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - bazedoxifene 20 mg/ conjugated estrogens 0.45 mg
Treatment: Drugs - bazedoxifene 20 mg/ conjugated estrogens 0.625 mg
Treatment: Drugs - bazedoxifene 20 mg
Treatment: Drugs - conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg
Treatment: Drugs - Placebo

Experimental: 1 - bazedoxifene 20 mg/conjugated estrogens 0.45 mg

Experimental: 2 - bazedoxifene 20 mg/conjugated estrogens 0.625 mg

Experimental: 3 - bazedoxifene 20 mg

Active comparator: 4 - Prempro

Placebo comparator: 5 - Placebo


Treatment: Drugs: bazedoxifene 20 mg/ conjugated estrogens 0.45 mg
One capsule, bazedoxifene 20 mg/conjugated estrogens 0.45 mg (over-encapsulated), once a day for one year.

Treatment: Drugs: bazedoxifene 20 mg/ conjugated estrogens 0.625 mg
One capsule, bazedoxifene 20 mg/conjugated estrogens 0.625 mg (over-encapsulated), once a day for one year.

Treatment: Drugs: bazedoxifene 20 mg
One capsule, bazedoxifene 20 mg (over-encapsulated), once a day for one year.

Treatment: Drugs: conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg
One capsule, conjugated estrogens 0.45 mg and medroxyprogesterone 1.5 mg (over-encapsulated), once a day for one year.

Treatment: Drugs: Placebo
One capsule, placebo (over-encapsulated), once a day for one year.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Endometrial Hyperplasia at Month 12: Main Study
Timepoint [1] 0 0
Month 12
Primary outcome [2] 0 0
Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 12: Osteoporosis Sub-Study
Timepoint [2] 0 0
Baseline, Month 12
Secondary outcome [1] 0 0
Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 6: Osteoporosis Sub-Study
Timepoint [1] 0 0
Baseline, Month 6
Secondary outcome [2] 0 0
Percent Change From Baseline in Bone Mineral Density (BMD) of Total Hip at Month 6, 12: Osteoporosis Sub-Study
Timepoint [2] 0 0
Baseline, Month 6, Month 12
Secondary outcome [3] 0 0
Percentage of Participants With Cumulative Amenorrhea: Main Study
Timepoint [3] 0 0
Day 1 up to Day 364
Secondary outcome [4] 0 0
Percent Change From Baseline in Breast Density at Month 12: Breast Density Sub-Study
Timepoint [4] 0 0
Baseline, Month 12
Secondary outcome [5] 0 0
Percent Change From Baseline in Bone Turnover Markers (BTMs) at Month 6 and Month 12: Osteoporosis Sub-Study
Timepoint [5] 0 0
Baseline, Month 6, 12
Secondary outcome [6] 0 0
Medical Outcomes Study (MOS) Sleep Scale at Baseline: Sleep Sub-Study
Timepoint [6] 0 0
Baseline
Secondary outcome [7] 0 0
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Month 3: Sleep Sub-Study
Timepoint [7] 0 0
Baseline, Month 3
Secondary outcome [8] 0 0
Menopause-Specific Quality of Life (MENQOL) Score at Baseline: Sleep Sub-Study
Timepoint [8] 0 0
Baseline
Secondary outcome [9] 0 0
Change From Baseline in Menopause-Specific Quality of Life (MENQOL) Score at Month 3: Sleep Sub-Study
Timepoint [9] 0 0
Baseline, Month 3
Secondary outcome [10] 0 0
Percentage of Participants With Uterine Bleeding
Timepoint [10] 0 0
Week 1-4, 5-8, 9-12, 13-16, 17-20, 21-24, 25-28, 29-32, 33-36, 37-40, 41-44, 45-48, 49-52

Eligibility
Key inclusion criteria
* Generally healthy, postmenopausal women, aged 40 to 64 seeking treatment for menopausal symptoms
* At least 12 months of spontaneous amenorrhea, OR 6 months spontaneous amenorrhea with follicle-stimulating hormone (FSH) levels > 40 mIU/mL
* Intact Uterus
Minimum age
40 Years
Maximum age
64 Years
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
* Use of oral estrogen, progestin, androgen, or selective estrogen receptor modulator (SERM) containing drug products within 8 weeks before screening
* A history or active presence of clinically important medical disease: eg. cardiovascular disease (stroke, heart attack), chronic renal or liver disease, breast cancer, etc.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/01/2009
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/02/2011
Sample size
Target
Accrual to date
Final
1886
Recruitment in Australia
Recruitment state(s)
NSW,WA
Recruitment hospital [1] 0 0
Pfizer Investigational Site - Randwick
Recruitment hospital [2] 0 0
Pfizer Investigational Site - St Leonards
Recruitment hospital [3] 0 0
Pfizer Investigational Site - Perth
Recruitment postcode(s) [1] 0 0
2031 - Randwick
Recruitment postcode(s) [2] 0 0
2065 - St Leonards
Recruitment postcode(s) [3] 0 0
6009 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Idaho
Country [10] 0 0
United States of America
State/province [10] 0 0
Illinois
Country [11] 0 0
United States of America
State/province [11] 0 0
Indiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Kansas
Country [13] 0 0
United States of America
State/province [13] 0 0
Kentucky
Country [14] 0 0
United States of America
State/province [14] 0 0
Maine
Country [15] 0 0
United States of America
State/province [15] 0 0
Michigan
Country [16] 0 0
United States of America
State/province [16] 0 0
Minnesota
Country [17] 0 0
United States of America
State/province [17] 0 0
Missouri
Country [18] 0 0
United States of America
State/province [18] 0 0
Montana
Country [19] 0 0
United States of America
State/province [19] 0 0
Nebraska
Country [20] 0 0
United States of America
State/province [20] 0 0
Nevada
Country [21] 0 0
United States of America
State/province [21] 0 0
New Hampshire
Country [22] 0 0
United States of America
State/province [22] 0 0
New Jersey
Country [23] 0 0
United States of America
State/province [23] 0 0
New Mexico
Country [24] 0 0
United States of America
State/province [24] 0 0
New York
Country [25] 0 0
United States of America
State/province [25] 0 0
North Carolina
Country [26] 0 0
United States of America
State/province [26] 0 0
North Dakota
Country [27] 0 0
United States of America
State/province [27] 0 0
Ohio
Country [28] 0 0
United States of America
State/province [28] 0 0
Oregon
Country [29] 0 0
United States of America
State/province [29] 0 0
Pennsylvania
Country [30] 0 0
United States of America
State/province [30] 0 0
Rhode Island
Country [31] 0 0
United States of America
State/province [31] 0 0
South Carolina
Country [32] 0 0
United States of America
State/province [32] 0 0
South Dakota
Country [33] 0 0
United States of America
State/province [33] 0 0
Tennessee
Country [34] 0 0
United States of America
State/province [34] 0 0
Texas
Country [35] 0 0
United States of America
State/province [35] 0 0
Utah
Country [36] 0 0
United States of America
State/province [36] 0 0
Virginia
Country [37] 0 0
United States of America
State/province [37] 0 0
Washington
Country [38] 0 0
Argentina
State/province [38] 0 0
Buenos Aires
Country [39] 0 0
Chile
State/province [39] 0 0
RM
Country [40] 0 0
Colombia
State/province [40] 0 0
Antioquia
Country [41] 0 0
Colombia
State/province [41] 0 0
Atlantico
Country [42] 0 0
Colombia
State/province [42] 0 0
Cundinamarca
Country [43] 0 0
Denmark
State/province [43] 0 0
Aalborg
Country [44] 0 0
Denmark
State/province [44] 0 0
Ballerup
Country [45] 0 0
Denmark
State/province [45] 0 0
Vejle
Country [46] 0 0
Finland
State/province [46] 0 0
Kuopio
Country [47] 0 0
Finland
State/province [47] 0 0
Oulu
Country [48] 0 0
Hungary
State/province [48] 0 0
Bekescsaba
Country [49] 0 0
Hungary
State/province [49] 0 0
Budapest
Country [50] 0 0
Hungary
State/province [50] 0 0
Debrecen
Country [51] 0 0
Hungary
State/province [51] 0 0
Kecskemet
Country [52] 0 0
Hungary
State/province [52] 0 0
Nyiregyhaza
Country [53] 0 0
Hungary
State/province [53] 0 0
Tatabanya
Country [54] 0 0
Mexico
State/province [54] 0 0
D.F
Country [55] 0 0
New Zealand
State/province [55] 0 0
NZ
Country [56] 0 0
New Zealand
State/province [56] 0 0
Christchurch
Country [57] 0 0
Norway
State/province [57] 0 0
Alesund
Country [58] 0 0
Norway
State/province [58] 0 0
Hamar
Country [59] 0 0
Poland
State/province [59] 0 0
Lublin
Country [60] 0 0
Poland
State/province [60] 0 0
Poznan
Country [61] 0 0
Poland
State/province [61] 0 0
Warszawa
Country [62] 0 0
Poland
State/province [62] 0 0
Wroclaw

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT00808132